Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis.

Cardiovascular disease represents one of the major causes of death across the global population. Atherosclerosis, one of its most common drivers, is characterized by the gradual buildup of arterial plaque over time, which can ultimately lead to life-threatening conditions. Given the impact of the disease on public health, there is a great need for effective and noninvasive imaging modalities that can provide valuable information on its biological underpinnings during development. Here, we leverage the role of platelets in atherogenesis to design nanocarriers capable of targeting multiple biological elements relevant to plaque development. Biomimetic nanoparticles are prepared by coating platelet membrane around a synthetic nanoparticulate core, the product of which is capable of interacting with activated endothelium, foam cells, and collagen. The effects are shown to be exclusive to platelet membrane-coated nanoparticles. These biomimetic nanocarriers are not only capable of efficiently localizing to well-developed atherosclerotic plaque, but can also target subclinical regions of arteries susceptible to plaque formation. Using a commonly employed magnetic resonance imaging contrast agent, live detection is demonstrated using an animal model of atherosclerosis. Ultimately, this strategy may be leveraged to better assess the development of atherosclerosis, offering additional information to help clinicians better manage the disease.

[1]  Ronnie H. Fang,et al.  Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. , 2016, Biomaterials.

[2]  M. Rayner,et al.  Cardiovascular disease in Europe: epidemiological update 2016. , 2016, European heart journal.

[3]  O. Tillement,et al.  Safety Evaluation and Imaging Properties of Gadolinium-Based Nanoparticles in nonhuman primates , 2016, Scientific Reports.

[4]  Damini Dey,et al.  Imaging of coronary atherosclerosis — evolution towards new treatment strategies , 2016, Nature Reviews Cardiology.

[5]  D. Zheng,et al.  Preferential Cancer Cell Self-Recognition and Tumor Self-Targeting by Coating Nanoparticles with Homotypic Cancer Cell Membranes. , 2016, Nano letters.

[6]  Andrew E Moran,et al.  Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013 , 2015, Circulation.

[7]  Ronnie H. Fang,et al.  Nanoparticle biointerfacing via platelet membrane cloaking , 2015, Nature.

[8]  D. Bluemke,et al.  Noninvasive Imaging of Atherosclerotic Plaque Progression: Status of Coronary Computed Tomography Angiography. , 2015, Circulation. Cardiovascular imaging.

[9]  Fei Wang,et al.  Detoxification of Organophosphate Poisoning Using Nanoparticle Bioscavengers. , 2015, ACS nano.

[10]  Ira Tabas,et al.  Recent insights into the cellular biology of atherosclerosis , 2015, The Journal of cell biology.

[11]  Mario J. Garcia,et al.  Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. , 2015, Journal of the American College of Cardiology.

[12]  Peter Seizer,et al.  Platelets in Inflammation and Atherogenesis , 2015, Front. Immunol..

[13]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[14]  G. Vilahur,et al.  Thrombosis formation on atherosclerotic lesions and plaque rupture , 2014, Journal of internal medicine.

[15]  Feng Gao,et al.  Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. , 2014, ACS nano.

[16]  Ronnie H. Fang,et al.  Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery , 2014, Nano letters.

[17]  E. Falk,et al.  Mechanisms of Plaque Formation and Rupture , 2014 .

[18]  Peter Scarborough,et al.  Cardiovascular disease in Europe: epidemiological update. , 2014, European heart journal.

[19]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[20]  G. Vilahur,et al.  Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease , 2012, European heart journal. Acute cardiovascular care.

[21]  Erling Falk,et al.  Non-invasive imaging of atherosclerosis. , 2012, European heart journal cardiovascular Imaging.

[22]  P. Hundelshausen,et al.  Platelets in atherosclerosis , 2011, Thrombosis and Haemostasis.

[23]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[24]  Y. Huang,et al.  Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake , 2010, Cytotechnology.

[25]  P. Shah,et al.  VIEWPOINT AND COMMENTARY Viewpoint Screening Asymptomatic Subjects for Subclinical Atherosclerosis Can We, Does It Matter, and Should We? , 2022 .

[26]  I. Tabas Macrophage death and defective inflammation resolution in atherosclerosis , 2010, Nature Reviews Immunology.

[27]  Robert Langer,et al.  Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.

[28]  T. Kooistra,et al.  Mouse models for atherosclerosis and pharmaceutical modifiers. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[29]  M. Gawaz,et al.  Platelets, inflammation and atherosclerosis , 2007, Journal of thrombosis and haemostasis : JTH.

[30]  Zahi A Fayad,et al.  Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI , 2007, Proceedings of the National Academy of Sciences.

[31]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[32]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[33]  J. Camm,et al.  [Guidelines on the management of stable angina pectoris: executive summary]. , 2006, Giornale italiano di cardiologia.

[34]  G. Desideri,et al.  Endothelial activation. Sliding door to atherosclerosis. , 2005, Current pharmaceutical design.

[35]  C. Weber Platelets and chemokines in atherosclerosis: partners in crime. , 2005, Circulation research.

[36]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[37]  K. Ley,et al.  Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.

[38]  M. Daemen,et al.  Atherosclerotic plaque rupture: local or systemic process? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[39]  F. Rank,et al.  PRIMARY PREVENTION OF CORONARY HEART DISEASE IN WOMEN THROUGH DIET AND LIFESTYLE , 2000 .

[40]  J L Witztum,et al.  The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. , 1992, Annual review of medicine.

[41]  J. Badimón,et al.  Atherosclerotic plaque rupture and thrombosis. Evolving concepts. , 1990, Circulation.

[42]  R. Ross The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[43]  Packham Ma,et al.  The role of platelets in the development and complications of atherosclerosis. , 1986, Seminars in hematology.

[44]  J. Mustard,et al.  The role of platelets in the development and complications of atherosclerosis. , 1986, Seminars in hematology.

[45]  V. Muzykantov,et al.  Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. , 1985, Collagen and related research.

[46]  V. Duance,et al.  The distribution of collagen types I, III and V (AB) in normal and atherosclerotic human aorta , 1980, The Journal of pathology.